This is latest turbt histopathological report Next line of management.

This is latest turbt histopathological report Next line of management. Patient has undergone turbt once before 2 years(it was LG papilllary ca without muscle invasion) Pro · 11 steps

Reading File

Running Command

python3 -c " import pdfplumber with pdfplumber.open('/tmp/workspace/attachments/dea7a5c0-b856-4c65-9150-39f0fa017a54/Turbt.pdf') as pdf: for i, page in enumerate(pdf.pages): print(f'--- Page {i+1} ---') print(page.extract_text()) "

Finding Sources

Searching PubMed

bladder cancer low grade recurrent non-muscle invasive management intravesical

Searching the Web

EAU guidelines 2025 non-muscle invasive bladder cancer recurrent low grade lamina propria invasion T1 management

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC12888563

I now have all the information needed for a thorough, guideline-based management plan. Let me compose the answer.

Histopathology Summary

Patient: Mr. Ashok R. Agrawal, Male, 55 years Specimen: TURBT - Superficial (Sp1) + Deep Muscle Biopsy (Sp2) Microscopy: Papillary fronds with fibrovascular core, fused papillae lined by multilayered urothelium (>7 layers), elongated hyperchromic nucleolated nuclei, moderate pale cytoplasm, basal mitosis. Lamina propria (lamina) invasion present. Muscularis propria NOT involved.

Final Impression: Lamina-invasive Low Grade Papillary Urothelial Carcinoma (pT1 LG)

Muscularis propria is free (confirms non-muscle invasive)

Staging & Risk Stratification

Feature	This Report	Previous TURBT (2 years ago)
Stage	pT1 (lamina invasion)	pTa (no lamina invasion)
Grade	Low Grade	Low Grade
Muscle invasion	Absent	Absent

Key change: This is a stage progression from Ta (confined to mucosa) to T1 (lamina propria invasion). Even though it is still low grade, T1 tumors are classified differently from Ta tumors in all major guidelines.

Risk group (EAU 2025): This patient falls into the Intermediate-Risk category at minimum (T1 LG), though some classification systems place T1 in the high-risk group regardless of grade, because lamina invasion carries higher recurrence and progression risk than Ta.

Next Line of Management

1. Re-TURBT (Mandatory - Top Priority)

A second TURBT (re-TURBT) within 2-6 weeks is strongly recommended - this is a strong recommendation across EAU 2025, AUA 2024, and NCCN 2025 guidelines (full concordance).

Reasons:

The initial TURBT may have incompletely resected T1 disease
Residual T1 tumor is found in 30-80% of cases at re-TURBT
Re-TURBT upstages ~10-15% of T1 LG to muscle-invasive disease (T2), which completely changes management
Adequate muscularis propria in the specimen is required for confident staging - here Sp2 (deep biopsy) showed no muscle invasion, which is reassuring, but formal re-TURBT is still standard practice

2. Intravesical BCG Therapy (Post-Re-TURBT)

Once re-TURBT confirms T1 LG (no upstaging to T2):

Intravesical BCG (Bacillus Calmette-Guerin) induction + maintenance is the standard adjuvant therapy for T1 disease
Standard regimen: 6-week induction course followed by 3-week maintenance at 3, 6, 12, 18, 24, 30, and 36 months (Lamm protocol - 3-year full maintenance)
BCG reduces recurrence and, importantly, progression to muscle-invasive disease
If BCG is unavailable (shortage), intravesical Gemcitabine + Docetaxel (Gem/Doce) is the preferred alternative per AUA 2024

If re-TURBT upstages to T2 (muscle-invasive), management shifts to radical cystectomy with neoadjuvant cisplatin-based chemotherapy - this is a completely different pathway.

3. Cystoscopy Surveillance Schedule

Per EAU/AUA guidelines for T1 disease:

Cystoscopy at 3 months after re-TURBT (this is critical - a positive 3-month cystoscopy is a strong predictor of progression)
Then every 3-6 months for 2 years
Then annually for life (given recurrence history)
CT Urography is also recommended to evaluate the upper urinary tract, as urothelial tumors can be multifocal

4. Urine Cytology

Perform urine cytology at baseline and at each follow-up cystoscopy
Cytology is particularly important to detect concurrent CIS (carcinoma in situ), which is a high-risk feature

Summary Flowchart

Current Report: T1 LG (lamina invasion, no muscle invasion)
        ↓
Re-TURBT in 2-6 weeks (mandatory)
        ↓
  ┌─────────────────────────────────┐
  │ Re-TURBT Result                 │
  ├──────────────┬──────────────────┤
  │ T1 or Ta     │ T2 (upstaged)    │
  │ (NMIBC)      │ (MIBC)           │
  ↓              ↓
BCG induction +  Radical cystectomy
maintenance      + Neoadjuvant chemo
  ↓
Surveillance cystoscopy
(3 mo → 6 mo → annual)

Clinical Note

The progression from pTa LG → pT1 LG over 2 years is significant. While still low grade, the acquisition of lamina propria invasion is a warning sign and warrants aggressive follow-through. Some urologists (and EAU guidelines) consider early cystectomy in patients with recurrent T1 disease, particularly if BCG fails after adequate therapy. Re-TURBT findings will be critical in guiding this decision.

Key references: EAU NMIBC Guidelines 2025 | EAU/AUA/NCCN Guideline Comparison (PMC)

This is a shared conversation. Sign in to Orris to start your own chat.